S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

$122.87
-1.58 (-1.27%)
(As of 04/12/2024 ET)

Sarepta Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings

Analysts' Consensus Price Target

$158.38
28.90% Upside
High Forecast$224.00
Average Forecast$158.38
Low Forecast$109.00
TypeCurrent Forecast
4/14/23 to 4/13/24
1 Month Ago
3/15/23 to 3/14/24
3 Months Ago
1/14/23 to 1/14/24
1 Year Ago
4/14/22 to 4/14/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
13 Buy rating(s)
14 Buy rating(s)
14 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$158.38$159.35$152.45$166.89
Predicted Upside28.90% Upside30.06% Upside39.21% Upside24.75% Upside
Get Sarepta Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

SRPT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SRPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Sarepta Therapeutics Stock vs. The Competition

TypeSarepta TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside28.90% Upside796.98% Upside10.17% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/1/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$164.00 ➝ $167.00+32.58%
2/29/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$128.00-2.54%
2/29/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$151.00 ➝ $157.00+20.09%
2/29/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$224.00+71.29%
2/29/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$160.00 ➝ $172.00+31.43%
2/29/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$141.00 ➝ $185.00+34.55%
2/29/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$169.00 ➝ $166.00+20.73%
2/20/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetIn-Line ➝ In-Line$108.00 ➝ $138.00+2.32%
2/14/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$130.00 ➝ $145.00+17.55%
1/31/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$170.00+42.75%
12/12/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$109.00+24.27%
10/31/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$211.00 ➝ $115.00+70.85%
10/31/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
10/31/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$183.00 ➝ $146.00+35.62%
6/23/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$176.00 ➝ $186.00+50.10%
5/24/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$151.00 ➝ $141.00+7.34%
4/26/2023Sumitomo Mitsui Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$185.00+50.05%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:29 PM ET.

SRPT Price Target - Frequently Asked Questions

What is Sarepta Therapeutics's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Sarepta Therapeutics stock is Moderate Buy based on the current 3 hold ratings and 12 buy ratings for SRPT. The average twelve-month price prediction for Sarepta Therapeutics is $158.38 with a high price target of $224.00 and a low price target of $109.00. Learn more on SRPT's analyst rating history.

Do Wall Street analysts like Sarepta Therapeutics more than its competitors?

Analysts like Sarepta Therapeutics more than other Medical companies. The consensus rating score for Sarepta Therapeutics is 2.80 while the average consensus rating score for medical companies is 2.68. Learn more on how SRPT compares to other companies.

Does Sarepta Therapeutics's stock price have much upside?

According to analysts, Sarepta Therapeutics's stock has a predicted upside of 30.85% based on their 12-month stock forecasts.

What analysts cover Sarepta Therapeutics?

Stock Ratings Reports and Tools

This page (NASDAQ:SRPT) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners